Cures Start Here. At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutchs pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nations first cancer prevention research program, as well as the clinical coordinating center of the Womens Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Careers Start Here.
At Fred Hutch, we believe that the innovation, collaboration, and rigor that result from diversity and inclusion are critical to our mission of eliminating cancer and related diseases. We seek employeeswho bringdifferent and innovativeways of seeing the world and solving problems.Fred Hutch is in pursuit of becoming an antiracist organization.Weare committed to ensuring that all candidates hired share our commitment to diversity,antiracism, and inclusion.
The post-doctoral research fellow will work on independent and collaborative projects in Dr. Chapuis' laboratory developing adoptive T cell immunotherapy within the Program in Immunology and Clinical Research Division at Fred Hutchinson Cancer Research Center. This highly translational research will involve the development of novel TCR-based cellular therapies for clinical translation; development of next-generation humanized murine models to gain insights into the in vivo barriers to effective therapy; and may include monitoring patients through-out the course of treatment with T cell therapies. Additionally, the successful applicant will employ strategies for improving current immunotherapy treatments, including and not limited to; cloning and characterizing T cell receptors (TCRs) specific for cancer-associated antigens, developing cutting-edge strategies for genetic modification of human T cells including CRISPR-based gene editing, and developing/testing new approaches for overcoming immunosuppressive signals in the tumor microenvironment.
Dr. Chapuis is a leader in the development and clinical application of adoptive immunotherapy using genetically modified T cells and is committed to the advancement of this approach. This is a full-time position with a salary based on the NIH scale and excellent benefits.
Cell Culture, cell sorting, flow cytometry, intracellular staining, and transfections
Molecular bench work with PCR, cloning, and vector design
NGS including, Single cell RNA sequencing, WEX, WGS
Validation through functional and killing assays
Write and submit grants and first author papers to peer reviewed journals
Stay current with relevant publications and apply knowledge to research
Compile data and synthesize innovative problem-solving methods
Collaborate and present data with a wide range of stakeholders and partners
Train others on protocols
Mentor and lead undergraduate and graduate students
Assist with lab maintenance and function
MD and/or a PhD in a biological science with a diverse knowledge of immunology
Proficient in immunology technique and knowhow
Strong scientific writing skills, ability to write and apply for funding opportunities and abstracts
Able to digest complex material and synthesize innovative ideas
Compile and clearly present data to an eclectic audience, both orally and written
Well versed in flow cytometry
Experience with molecular techniques lentiviral modification of T cells
Experience in analysis of TCR signaling pathways and T cell function
Experience with in vivo murine experimentation
Familiarity with biostatistics, R and Python languages
Ability to derive and maintain T cell tissue cultures
Have a good understanding of SRAs and/or phase I/II clinical trials
To be successful, the post-doctoral research fellow must be: highly motivated and driven, able to work independently and with others, be open to receive and provide feedback for scientific discussion and general lab work, possess an acute attention to detail and organizational skills, think critically and problem solve and be excellent at note taking and reproducibility.
A statement describing your commitment and contributions toward greater diversity, equity, inclusion, and anti-racism in your career or that will be made through work at Fred Hutch is requested of all finalists.
Our Commitment to Diversity
We are proud to be an Equal Employment Opportunity (EEO) and Vietnam Era Veterans Readjustment Assistance Act (VEVRAA) Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability (physical or mental), marital or veteran status, genetic information, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. If due to a disability you need assistance/and or a reasonable accommodation during the application or recruiting process, please send a request to our Employee Services Center at email@example.com or by calling 206-667-4700.
At Fred Hutchinson Cancer Research Center, teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Researchers are discovering new ways to detect cancers earlier, improve treatments, and learn how to prevent cancers from growing. Although Fred Hutchinson opened its doors in 1975, its history began about 20 years before that. In 1962 Fred Hutchinson envisioned a center devoted to studying cancer, a disease that took his brother’s life. Today Fred Hutchinson is contributing to the next waves of breakthrough treatments and prevention strategies. Fred Hutchinson collaborates with the Seattle Cancer Alliance, the National Cancer Institute, and the University of Washington.